digiM is a software and tech-enabled services company that helps teams accelerate drug development. It uses advanced imaging techniques to capture the microstructure of diverse dosage forms, and predicts product performance from those images. This in vitro in silico approach reduces reliance on trial-and-error testing, supports a deeper understanding of both early- and late-stage drug products, and enhances regulatory filing, product life cycle management, and intellectual property positions. To learn more, click here. | 
